Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$22.38
0.281.27%
At close: -
$22.57
0.190.85%
After Hours: 7:56 PM EDT
Comments
Loading...
Structure Therapeutics Analyst Ratings and Price Targets | NASDAQ:GPCR | Benzinga
Structure Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Structure Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Cantor Fitzgerald
JMP Securities
HC Wainwright & Co.
Citigroup
Citizens Capital Markets
1calculated from analyst ratings
Analyst Ratings for Structure Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/23/2025 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/23/2025 | Buy Now | — | JMP Securities | Jonathan Wolleben71% | $89 → $89 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/12/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | $80 → $75 | Maintains | Buy | Get Alert |
| 05/02/2025 | Buy Now | — | Citigroup | Samantha Semenkow31% | → $60 | Initiates | → Buy | Get Alert |
| 04/22/2025 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | $80 → $80 | Maintains | Buy | Get Alert |
| 02/28/2025 | Buy Now | — | Citizens Capital Markets | Jonathan Wolleben71% | $91 → $87 | Maintains | Market Outperform | Get Alert |
| 02/28/2025 | Buy Now | — | William Blair | Andy Hsieh26% | — | Initiates | → Outperform | Get Alert |
| 01/08/2025 | Buy Now | — | Stifel | Annabel Samimy66% | → $50 | Initiates | → Buy | Get Alert |
| 12/20/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | $80 → $80 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben71% | $91 → $91 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/04/2024 | Buy Now | — | HC Wainwright & Co. | Andrew Fein61% | → $80 | Initiates | → Buy | Get Alert |
| 09/23/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/23/2024 | Buy Now | — | Morgan Stanley | Terence Flynn64% | → $118 | Initiates | → Overweight | Get Alert |
| 09/16/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 09/09/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/15/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben71% | $91 → $86 | Maintains | Market Outperform | Get Alert |
| 07/01/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 06/07/2024 | Buy Now | — | BMO Capital | Evan David Seigerman48% | $83 → $100 | Maintains | Outperform | Get Alert |
| 06/03/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 05/21/2024 | Buy Now | — | JP Morgan | Hardik Parikh10% | → $65 | Initiates | → Overweight | Get Alert |
| 05/10/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben71% | $91 → $91 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/03/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 04/18/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | $65 → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 04/09/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal43% | → $65 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben71% | $91 → $91 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/20/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben71% | → $91 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/15/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben71% | $90 → $91 | Maintains | Market Outperform | Get Alert |
| 10/27/2023 | Buy Now | — | Piper Sandler | Yasmeen Rahimi59% | $58 → $93 | Maintains | Overweight | Get Alert |
| 10/26/2023 | Buy Now | — | Piper Sandler | Yasmeen Rahimi59% | $58 → $93 | Maintains | Overweight | Get Alert |
| 10/19/2023 | Buy Now | — | JMP Securities | Jonathan Wolleben71% | → $90 | Initiates | → Market Outperform | Get Alert |
| 10/03/2023 | Buy Now | — | BMO Capital | Evan David Seigerman48% | $40 → $83 | Maintains | Outperform | Get Alert |
| 09/29/2023 | Buy Now | — | Jefferies | Chris Howerton62% | $50 → $79 | Maintains | Buy | Get Alert |
| 07/27/2023 | Buy Now | — | Piper Sandler | Yasmeen Rahimi59% | → $58 | Initiates | → Overweight | Get Alert |
| 02/28/2023 | Buy Now | — | Guggenheim | Seamus Fernandez61% | → $50 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | — | BMO Capital | Evan Seigerman63% | → $40 | Initiates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | — | Jefferies | Chris Howerton62% | → $34 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Structure Therapeutics (GPCR) stock?
The latest price target for Structure Therapeutics (NASDAQ:GPCR) was reported by Cantor Fitzgerald on June 23, 2025. The analyst firm set a price target for $65.00 expecting GPCR to rise to within 12 months (a possible 187.99% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Structure Therapeutics (GPCR)?
The latest analyst rating for Structure Therapeutics (NASDAQ:GPCR) was provided by Cantor Fitzgerald, and Structure Therapeutics reiterated their overweight rating.
When was the last upgrade for Structure Therapeutics (GPCR)?
There is no last upgrade for Structure Therapeutics
When was the last downgrade for Structure Therapeutics (GPCR)?
There is no last downgrade for Structure Therapeutics.
When is the next analyst rating going to be posted or updated for Structure Therapeutics (GPCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Structure Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Structure Therapeutics was filed on June 23, 2025 so you should expect the next rating to be made available sometime around June 23, 2026.
Is the Analyst Rating Structure Therapeutics (GPCR) correct?
While ratings are subjective and will change, the latest Structure Therapeutics (GPCR) rating was a reiterated with a price target of $65.00 to $65.00. The current price Structure Therapeutics (GPCR) is trading at is $22.57, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
